Zymeworks Opens R&D Lab for ADCs
By

Zymeworks, a Vancouver, Canada-headquartered clinical-stage biopharmaceutical company, has opened a new 10,000-square-foot laboratory facility in Vancouver, Canada, for developing antibody drug conjugates (ADCs).

The new lab will provide the company with increased control over discovery research, antibody generation, medicinal chemistry, and bioconjugation for generating ADCs as well as for developing multi-functional proteins.

Source: Zymeworks

Leave a Reply

Your email address will not be published.